RA Session II
2021
In 2021, RA Session II earned a total compensation of $4.6M as President, Chief Executive Officer and Director at Taysha Gene Therapies, a 3% decrease compared to previous year.
Compensation breakdown
| Option Awards | $4,028,250 |
|---|---|
| Salary | $542,800 |
| Other | $150 |
| Total | $4,571,200 |
Session received $4M in option awards, accounting for 88% of the total pay in 2021.
Session also received $542.8K in salary and $150 in other compensation.
Rankings
In 2021, RA Session II's compensation ranked 2,899th out of 12,415 executives tracked by ExecPay. In other words, Session earned more than 76.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,899 out of 12,415 | 77th |
Division Manufacturing | 1,154 out of 5,508 | 79th |
Major group Chemicals And Allied Products | 460 out of 2,378 | 81st |
Industry group Drugs | 404 out of 2,099 | 81st |
Industry Biological Products, Except Diagnostic Substances | 116 out of 449 | 74th |
Source: SEC filing on April 28, 2022.
Session's colleagues
We found two more compensation records of executives who worked with RA Session II at Taysha Gene Therapies in 2021.